X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Aura’s lead VDC candidate, Bel-sar (belzupacap sarotalocan) consists of a virus-like particle conjugated with an anti-cancer agent. Currently, it is being evaluating under Phase III clinical trial studies for treatment of adult patients with early-stage choroidal melanoma.
Lead Product(s): Belzupacap Sarotalocan
Therapeutic Area: Oncology Product Name: Bel-sar
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
The net proceeds will be used to advance the clinical development of Bel-sar (belzupacap sarotalocan), a novel investigational agent designed with a dual MOA that includes targeted cytotoxicity and immune activation, for the treatment of choroidal melanoma.
Lead Product(s): Belzupacap Sarotalocan
Therapeutic Area: Oncology Product Name: Bel-sar
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $99.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 06, 2023
Details:
Bel-sar (belzupacap sarotalocan), consists of a virus-like particle conjugated with an anti-cancer agent. It is designed to selectively target and destroy cancer cells and activate the immune system with long-lasting anti-tumor immunity.
Lead Product(s): Belzupacap Sarotalocan
Therapeutic Area: Oncology Product Name: AU-011
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
AU-011 (belzupacap sarotalocan), a first-in-class targeted therapy, is in development for the treatment of primary ocular melanoma, a rare and life-threatening disease. The therapy consists of viral nanoparticle conjugates that bind selectively to cancer cells in the eye.
Lead Product(s): Belzupacap Sarotalocan
Therapeutic Area: Oncology Product Name: AU-011
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $80.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 30, 2022
Details:
Aura’s lead VDC candidate, belzupacap sarotalocan (bel-sar; AU-011), consists of a virus-like particle conjugated with an anti-cancer agent. Bel-sar is designed to selectively target and destroy cancer cells and activate the immune system.
Lead Product(s): Belzupacap Sarotalocan
Therapeutic Area: Oncology Product Name: AU-011
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
AU-011 (Bel-Sar; belzupacap sarotalocan), consists of virus-like particle conjugated designed to selectively target and destroy cancer cells and activate the immune system with the potential to create long-lasting anti-tumor immunity.
Lead Product(s): Belzupacap Sarotalocan
Therapeutic Area: Oncology Product Name: AU-011
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
belzupacap sarotalocan (AU-011), consists of a virus-like particle conjugated with an anti-cancer agent. Belzupacap sarotalocan selectively targets and destroys cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity.
Lead Product(s): Belzupacap Sarotalocan
Therapeutic Area: Oncology Product Name: AU-011
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
AU-011 (belzupacap sarotalocan) is designed to selectively target and destroy cancer cells and activate the immune system with the potential to create long-lasting anti-tumor immunity.
Lead Product(s): Belzupacap Sarotalocan
Therapeutic Area: Oncology Product Name: AU-011
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
Belzupacap sarotalocan (AU-011), consists of a virus-like particle conjugated with an anti-cancer agent, is designed to selectively target and destroy cancer cells and activate the immune system with the potential to create long-lasting anti-tumor immunity.
Lead Product(s): Belzupacap Sarotalocan
Therapeutic Area: Oncology Product Name: AU-011
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2022
Details:
Comparison of AU-011 (belzupacap sarotalocan) and radiotherapy results supports potential benefit targeted treatment achieving statistically significant difference in visual acuity preservation as soon as two years including for both logMAR vision and change in logMAR vision.
Lead Product(s): Belzupacap Sarotalocan
Therapeutic Area: Oncology Product Name: AU-011
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
